Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice

• Published in: ACS omega Vol. 7; no. 36; pp. 31935 - 31944
• Main Authors: Puhl, Ana C., Gomes, Giovanni F., Damasceno, Samara, Fritch, Ethan J., Levi, James A., Johnson, Nicole J., Scholle, Frank, Premkumar, Lakshmanane, Hurst, Brett L., Lee-Montiel, Felipe, Veras, Flavio P., Batah, Sabrina S., Fabro, Alexandre T., Moorman, Nathaniel J., Yount, Boyd L., Dickmander, Rebekah J., Baric, Ralph S., Pearce, Kenneth H., Cunha, Fernando Q., Alves-Filho, José C., Cunha, Thiago M., Ekins, Sean
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 13.09.2022

The portfolio of SARS-CoV-2 small molecule drugs is currently limited to a handful that are either approved (remdesivir), emergency approved (dexamethasone, baricitinib, paxlovid, and molnupiravir), or in advanced clinical trials. Vandetanib is a kinase inhibitor which targets the vascular endotheli...